Notes for P&L

All amounts in SEKm unless otherwise stated

Note 19 Non-current finanical assets


Download Excel

          Parent Company
Receivables from Group companies 2020-12-31 2019-12-31
Opening balance 1,278.0 1,027.9
Increase during the year 731.9 419.5
Decrease during the year -300.7 -169.4
Carrying amount at year-end 1,709.2 1,278.0
             
Specification of interests in Group companies Country Number of shares Quotient value Holding % Carrying amount 2020-12-31 Carrying amount 2019-12-31
AddLife Development AB Sweden 1,000 100 100% 389.1 389.1
Biomedica Holding GmbH Austria 37,500 1 0% 416.5
 
Interests in Group companies Parent Company
Accumulated cost 2020 2019
Opening balance 805.6 797.6
Acquisitions for the year 8.0
Disposals for the year¹ -416.5
Closing balance 389.1 805.6
¹ Internal sale of Biomedica Holding GmbH to AddLife Development AB

Download Excel

Indirect ownership
Indirect ownership Ownership   Indirect ownership Ownership   Indirect ownership Ownership
Biomedica Medizinprodukte GmbH 100%   Mediplast GmbH 100%   Lab-Vent Controls A/S 100%
Biomedica Services AG 100%   Mediplast Holding Aps 100%   Koldt & Ryø El A/S 100%
Biomedica Medizintechnik AG 100%   Mediplast A/S 100%   Immuno Diagnostics Oy 100%
Euromed Swiss AG 100%   Hospidana A/S 100%   Bergman Diagnostika AS 100%
Biomedis d.o.o. 100%   Fenno Medical Oy 100%   BioNordika (Denmark) A/S 100%
Biomedica MP d.o.o. 100%   Svan Care AB 100%   BioNordika Bergman AS 100%
Biomedica Dijagnostika doo 100%   Hepro AS 100%   BioNordika (Sweden) AB 100%
Biomedica d.o.o. 100%   Esthe-Tech AB 100%   BioNordika (Finland) Oy 100%
Biomedica Bulgaria ood 100%   V-tech AB 100%   Funksjonsutstyr AS 76%
Biomedica Medizinprodukte Romania SRL 100%   Väinö Korpinen Oy 100%   EuroClone S.p.A. 100%
Biomedica Hungaria Kft. 100%   Triolab Oy 100%   TechniPro PulmoMed Pty Ltd 100%
Biomedica CS s.r.o. 100%   Triolab AB 100%   Ropox A/S 100%
Biomedica Poland Sp. Zo.o. 100%   Triolab (Baltics) Oy 100%   Dach Medical Group Holding AG 100%
Biomedica Dijagnostika d.o.o.el 100%   LabRobot Products AB 100%   Dach Austria Medical Group GmbH 100%
Biomedica Slovakita s.r.o. 80%   BergmanLabora AB 100%   Dach Switzerland Medical Group GmbH 100%
Mediplast AB 100%   Biolin Scientific AB 100%   D-A-CH Germany Medical Group GmbH 100%
Mediplast AS 100%   Biolin Scientific China 100%   Zafe Care Systems AB 100%
Mediplast Sataside Oy 100%   Biolin Scientific Oy 100%   Biomedica Italia s.r.l 100%
Mediplast S.r.l 100%   Biolin Scientific LTD 100%      
Mediplast Benelux B.V. 100%   Holm & Halby A/S 100%      

Accounting principle

Interests in Group companies are recognised in the Parent Company using the cost method, which means that transaction costs are included in the carrying amount for holdings in subsidiaries. Any changes in liabilities for contingent consideration are added to or reduce the (acquisition) cost. In the Group, transaction costs are expensed and changes in liabilities for contingent considerations are entered as income or expense. Shareholder contributions provided by the Parent Company are recognized in shares, when impairment is not required. 

 

To the top